Figures computed from official regulatory filings — .
Analysttarget 18 USD (+389%)
Ownershipinsiders 0.11% · institutions 2.38% · short 4.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for ARISTOTLE CORP only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
53 buys152 sellsbar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| NETTER DONALD T | Other | n/a (No price was disclosed in the filing) | SEC | ||
| NETTER DONALD T |
| Other |
| n/a (No price was disclosed in the filing) |
| SEC |
| NETTER DONALD T | Other | n/a (No price was disclosed in the filing) | SEC |
| Harkavy Ira R | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| JOHNSON DEAN T | Other | n/a (No price was disclosed in the filing) | SEC |
| LAHEY JOHN L | Other | n/a (No price was disclosed in the filing) | SEC |
| NIEMEYER W PHILLIP | Other | n/a (No price was disclosed in the filing) | SEC |
| LAHEY JOHN L | Other | n/a (No price was disclosed in the filing) | SEC |
| SCHLIER BRIAN | Other | n/a (No price was disclosed in the filing) | SEC |
| LAHEY JOHN L | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| LAHEY JOHN L | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| TATUM JAMES G | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| JOHNSON DEAN T | Other | n/a (No price was disclosed in the filing) | SEC |
| NASCO HOLDINGS, INC. | Award | n/a (No price was disclosed in the filing) | SEC |
| Whritner John A | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| LAPIN STEVEN B | Other | n/a (No price was disclosed in the filing) | SEC |
| Whritner John A | Other | n/a (No price was disclosed in the filing) | SEC |
| LAPIN STEVEN B | Other | n/a (No price was disclosed in the filing) | SEC |
| NASCO HOLDINGS, INC. | Award | n/a (No price was disclosed in the filing) | SEC |
| LRTA, INC. | Other | n/a (No price was disclosed in the filing) | SEC |
| TATUM JAMES G | Other | n/a (No price was disclosed in the filing) | SEC |
| SMITH H WILLIAM | Other | n/a (No price was disclosed in the filing) | SEC |
| Harkavy Ira R | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| NIEMEYER W PHILLIP | Other | n/a (No price was disclosed in the filing) | SEC |
| NASCO HOLDINGS, INC. | Award | n/a (No price was disclosed in the filing) | SEC |